Erschienen in:
01.09.2005
Invited Commentary
verfasst von:
Peter M. Schlag, M.D., Ph.D.
Erschienen in:
World Journal of Surgery
|
Ausgabe 9/2005
Einloggen, um Zugang zu erhalten
Excerpt
Sentinel lymph node biopsy (SLNB) using peritumoral dye or radiotracer injection promises to improve lymph node staging in patients with solid tumors. Thus far, the procedure has been mainly validated for malignant melanoma and breast cancer [
1]. For these tumors, the indication and the extent of lymph node dissection can be tailored on the basis of SLNB results. However, the value of using this method in the treatment of colorectal cancer is still controversial [
2,
3]. The current experience shows that SLNB in patients with colon cancer contributes to sophisticated staging by permitting focused histopathologic examinations and a rational use of immunohistochemical staining for occult metastases [
2,
4,
5]. …